Stockscreener 앱 받기
5.29
1.12%
-0.06
시간 외 거래:
5.30
0.010
+0.19%
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks
Verastem's Fast-Track KRAS G12D Inhibitor: A Strategic Play in a High-Unmet-Need Oncology Market - AInvest
Verastem Oncology gets FDA fast track status for cancer drug - Seeking Alpha
Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA - Contract Pharma
FDA grants fast track designation to Verastem’s pancreatic cancer drug By Investing.com - Investing.com Canada
FDA Fast Track Boosts Verastem's Breakthrough Pancreatic Cancer Drug Targeting Critical KRAS Mutation - Stock Titan
Published on: 2025-07-24 00:31:57 - Autocar Professional
Is Verastem Inc. a good long term investmentConsistent high-yield stocks - Autocar Professional
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
What analysts say about Verastem Inc. stockFree Expert Stock Watchlist - Autocar Professional
What drives Verastem Inc. stock priceUnmatched profit potential - Autocar Professional
Verastem Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
(VSTM) Proactive Strategies - news.stocktradersdaily.com
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha
Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance
Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest
Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada
Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com
Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance
KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com
Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest
Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener
Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan
Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks
Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks
How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com
Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks
3.32%
1.57%
자본화:
|
볼륨(24시간):